322 related articles for article (PubMed ID: 12925698)
1. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
2. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
3. Decrypting the role of Cripto in tumorigenesis.
Shen MM
J Clin Invest; 2003 Aug; 112(4):500-2. PubMed ID: 12925690
[TBL] [Abstract][Full Text] [Related]
4. Cell-type specific regulation of myostatin signaling.
Kemaladewi DU; de Gorter DJ; Aartsma-Rus A; van Ommen GJ; ten Dijke P; 't Hoen PA; Hoogaars WM
FASEB J; 2012 Apr; 26(4):1462-72. PubMed ID: 22202673
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into the interaction between the Cripto CFC domain and the ALK4 receptor.
Calvanese L; Saporito A; Oliva R; D' Auria G; Pedone C; Paolillo L; Ruvo M; Marasco D; Falcigno L
J Pept Sci; 2009 Mar; 15(3):175-83. PubMed ID: 19035567
[TBL] [Abstract][Full Text] [Related]
6. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
Kelber JA; Shani G; Booker EC; Vale WW; Gray PC
J Biol Chem; 2008 Feb; 283(8):4490-500. PubMed ID: 18089557
[TBL] [Abstract][Full Text] [Related]
7. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis.
Strizzi L; Bianco C; Normanno N; Salomon D
Oncogene; 2005 Aug; 24(37):5731-41. PubMed ID: 16123806
[TBL] [Abstract][Full Text] [Related]
8. Cripto monoclonal antibodies.
Hu XF; Xing PX
Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
[TBL] [Abstract][Full Text] [Related]
9. A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src.
Bianco C; Strizzi L; Rehman A; Normanno N; Wechselberger C; Sun Y; Khan N; Hirota M; Adkins H; Williams K; Margolis RU; Sanicola M; Salomon DS
Cancer Res; 2003 Mar; 63(6):1192-7. PubMed ID: 12649175
[TBL] [Abstract][Full Text] [Related]
10. The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. Functional and structural insights through disulfide structure analysis.
Foley SF; van Vlijmen HW; Boynton RE; Adkins HB; Cheung AE; Singh J; Sanicola M; Young CN; Wen D
Eur J Biochem; 2003 Sep; 270(17):3610-8. PubMed ID: 12919325
[TBL] [Abstract][Full Text] [Related]
11. Cripto localizes Nodal at the limiting membrane of early endosomes.
Blanchet MH; Le Good JA; Oorschot V; Baflast S; Minchiotti G; Klumperman J; Constam DB
Sci Signal; 2008 Nov; 1(45):ra13. PubMed ID: 19001664
[TBL] [Abstract][Full Text] [Related]
12. Cripto-independent Nodal signaling promotes positioning of the A-P axis in the early mouse embryo.
Liguori GL; Borges AC; D'Andrea D; Liguoro A; Gonçalves L; Salgueiro AM; Persico MG; Belo JA
Dev Biol; 2008 Mar; 315(2):280-9. PubMed ID: 18241853
[TBL] [Abstract][Full Text] [Related]
13. Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells.
Parisi S; D'Andrea D; Lago CT; Adamson ED; Persico MG; Minchiotti G
J Cell Biol; 2003 Oct; 163(2):303-14. PubMed ID: 14581455
[TBL] [Abstract][Full Text] [Related]
14. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms.
Yeo C; Whitman M
Mol Cell; 2001 May; 7(5):949-57. PubMed ID: 11389842
[TBL] [Abstract][Full Text] [Related]
15. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway.
Yan YT; Liu JJ; Luo Y; E C; Haltiwanger RS; Abate-Shen C; Shen MM
Mol Cell Biol; 2002 Jul; 22(13):4439-49. PubMed ID: 12052855
[TBL] [Abstract][Full Text] [Related]
16. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.
Gray PC; Shani G; Aung K; Kelber J; Vale W
Mol Cell Biol; 2006 Dec; 26(24):9268-78. PubMed ID: 17030617
[TBL] [Abstract][Full Text] [Related]
17. Cripto: a novel target for antibody-based cancer immunotherapy.
Xing PX; Hu XF; Pietersz GA; Hosick HL; McKenzie IF
Cancer Res; 2004 Jun; 64(11):4018-23. PubMed ID: 15173016
[TBL] [Abstract][Full Text] [Related]
18. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells.
Bianco C; Adkins HB; Wechselberger C; Seno M; Normanno N; De Luca A; Sun Y; Khan N; Kenney N; Ebert A; Williams KP; Sanicola M; Salomon DS
Mol Cell Biol; 2002 Apr; 22(8):2586-97. PubMed ID: 11909953
[TBL] [Abstract][Full Text] [Related]
19. Non-cell-autonomous role for Cripto in axial midline formation during vertebrate embryogenesis.
Chu J; Ding J; Jeays-Ward K; Price SM; Placzek M; Shen MM
Development; 2005 Dec; 132(24):5539-51. PubMed ID: 16291788
[TBL] [Abstract][Full Text] [Related]
20. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto.
Harms PW; Chang C
Genes Dev; 2003 Nov; 17(21):2624-9. PubMed ID: 14563676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
